In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 1, 1998, Pages 447-458

  Graham, Mark J ^a   Crooke, Stanley T ^a   Monteith, David K ^a   Cooper, Scott R ^a   Lemonidis, Kristina M ^a   Stecker, Kim K ^a   Martin, Michael J ^a   Crooke, Rosanne M ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISIS 1082; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL FRACTIONATION; CELLULAR DISTRIBUTION; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG METABOLISM; ENDOTHELIUM CELL; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; MALE; NONHUMAN; NUCLEOTIDE METABOLISM; NUCLEOTIDE TRANSPORT; PRIORITY JOURNAL; RAT; SEQUENCE ANALYSIS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; LIVER; MALE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, SPRAGUE-DAWLEY; THIONUCLEOTIDES;

EID: 0031821074     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Agrawal S, Temsamani J, Galbraith W and Tang. (1995) Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28:7-16.
2. Benimetskaya L, Tonkinson JL, Koziolkicwicz M, Karwowski B, Guga P, Zeltser R, Stec W and Stein CA (1995) Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res 23:4239-4245.
3. Berger SL and Chirgwin JM (1989) Isolation of RNA, in Methods in Enzymology: Vol. 180, RNA Processing, Part A, General Methods (Dahlberg JE and Abelson JN eds) pp 3-13, Academic Press, Inc, San Diego, CA.
4. Berry MN and Friend DS (1972) High yield preparation of isolated rat liver parenchymal cells: A biochemical and fine structure analysis. J Cell Biol 59:722-734.
5. Bijsterbosch MK, Manoharan M, Rump ET, De Vrueh RLA, Veghel RV, Tivel KL, Biessen EAL, Bennett FL, Cook PD and Berkel TJC (1997) In vivo fate of phosphorthioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial cells. Nucleic Acid Res 25:3290-3296.
6. Butler M, Stecker K and Bennett FC (1997) Cellular Distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 77:379-388.
7. Carome MA, Kang Y, Bohen EM, Nicholson DE, Carr FE, Kiandoli LC, Brummel SE and Yuan CM (1997) Distribution of the cellular uptake of phosphorothioate oligonucleotides in the rat kidney in vivo. Nephron 75:82-87.
8. Crooke RM (1993) Cellular uptake, distribution and metabolism of phosphorothioate, phosphodiester and methylphosphonate oligonucleotides, in Antisense Research and Applications (Crooke ST and LeBleu B eds) pp 427-460, CRC Press, Boca Raton, FL..
9. Crooke RM, Graham MJ, Cooke ME and Crooke ST (1995) In Vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther 275:462-473.
10. Crooke ST (1995) Oligonucleotides as potential therapeutic agents, in Trends and Future Perspectives in Peptides and Protein Drug Delivery (Lee VHL, Hashida M and Mizushima Y eds) pp 297-320, Harwood Academic Publishers, Switzerland.
11. Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Grieg MJ, Guinosso CJ, Kornburst D, Maonoharan M, Sasmor HM, Schliech T, Tivel KL and Griffey RH (1996) Pharmacokinetic properties of several novel oligonucleotides in mice. J Pharmacol Exp Ther 277:923-937, 1996.
12. Dean NM and McKay R (1994) Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligonucleotides. Proc Natl Acad Sci USA 91:16416-16424.
13. Deschenes J, Valet JP and Mareceau N (1980) Hepatocytes from newborn and weanling rats in monolayer culture: Isolation by perfusion, fibronectin-mediated adhesion, spreading and functional activities. In Vitro 16:722-730.
14. Garvey JS and Caperna TJ (1981) Collection and enrichment of kupffer cells, Manual of Macophage Methodology (Herscowitz HB, Holden HT, Bellanti JA and Ghaffer A eds) pp 31-35, Marcel Dekker, Inc., New York.
15. Geary RS, Leeds JM, Fitchett J, Burckin T, Troung L, Spainhour C, Creek M and Levin AA (1997a) Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of c-raf-1 kinase expression. Drug Metab Dispos 25:1272-1281.
16. Glover JM, Leeds JM, Mant TGK, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA and Shanahan WR Jr (1997) Phase 1 safety and pharamacokinetic profile of an intercellular adhesion molecule-1 antisense oligonucleotide (ISIS 2302). J Pharmacol Exp Ther 282:1173-1180.
17. Inagaki M, Togawa K, Carr, Ghosh K and Cohen JS (1992) Antisense oligonucleotides: inhibition of liver cell proliferation and in vivo disposition. Transplant Proc 24:2971-2972.
18. Iverson PL, Copple BL and Tewary HK (1995) Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicol Lett 82:425-430.
19. 3H-1,2-benzodithiole-3-one 1.1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates. J Am Chem Soc 112:1253-1254.
20. Leeds JM, Graham MJ, Truong L and Cummins LL (1996) Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 235:36-43.
21. Nestle FO, Mitra RS, Bennett FC, Chan H and Nickoloff BJ (1994) Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol 4:569-575.
22. Nicklin PL, Craig SJ and Phillips JA (1998) Pharmacokinetic properties of phosphorothioates in animals - absorption, distribution, metabolism and elimination, in Handbook of Experimental Pharmacology, Antisense Research and Application (in press).
23. Plenat F, Klein-Monohoven N, Marie, Vignaud J and Duprez A (1995) Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. Am J Pathol 147:124-135.
24. Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM and Klotman PE (1995) Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney Int 47:1462-1469.
25. Rifai A, Brysch W, Fadden K, Clark J and Schlingensiepen K (1996) Clearance kinetics, biodistribution and organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am J Pathol 149:717-725.
26. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and phosphorothioate. Mol Pharm 45:932-943.
27. Seglen PO (1976) Preparation of isolated rat liver cells.: Methods Cell Biol 13:29-83.
28. Seljelid R and Smedsrød. (1981) Obtaining kupffer cells, in Methods for Studying Mononuclear Phagocytes (Adams DO, Edelson PJ and Koren H eds) pp 97-101, Academic Press, New York.
29. Spitzer S and Eckstein F (1988) Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxynucleotides. Nucleic Acids Res 16:11691-11704.
30. Wu-Pong S, Weiss TL and Hunt CA (1994) Antisense c-myc oligonucleotide cellular uptake and activity. Antisense Res Dev 4:155-163.